MML Investors Services LLC Cuts Position in Haleon plc (NYSE:HLN)

MML Investors Services LLC lowered its stake in shares of Haleon plc (NYSE:HLN - Free Report) by 15.4% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 292,782 shares of the company's stock after selling 53,465 shares during the period. MML Investors Services LLC's holdings in Haleon were worth $3,098,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the stock. Fortitude Family Office LLC acquired a new stake in shares of Haleon during the 3rd quarter worth about $28,000. Cultivar Capital Inc. purchased a new stake in Haleon in the 2nd quarter worth approximately $40,000. Prospera Private Wealth LLC acquired a new position in Haleon in the 3rd quarter valued at $57,000. BOKF NA lifted its stake in shares of Haleon by 68.8% during the 2nd quarter. BOKF NA now owns 6,972 shares of the company's stock worth $58,000 after purchasing an additional 2,842 shares during the period. Finally, Rothschild Investment LLC acquired a new stake in shares of Haleon during the second quarter worth $60,000. Hedge funds and other institutional investors own 6.67% of the company's stock.

Haleon Trading Up 0.3 %

Shares of NYSE HLN traded up $0.03 during trading on Friday, hitting $9.76. 11,526,562 shares of the company traded hands, compared to its average volume of 5,403,752. The company has a quick ratio of 0.58, a current ratio of 0.84 and a debt-to-equity ratio of 0.44. The firm has a market capitalization of $44.18 billion, a P/E ratio of 28.71, a P/E/G ratio of 2.95 and a beta of 0.28. The company has a 50-day moving average price of $9.75 and a 200-day moving average price of $9.53. Haleon plc has a 1 year low of $7.89 and a 1 year high of $10.80.

Analyst Upgrades and Downgrades

HLN has been the subject of several analyst reports. Morgan Stanley upped their target price on Haleon from $9.90 to $10.95 and gave the company an "overweight" rating in a research note on Friday, September 20th. UBS Group raised shares of Haleon to a "strong-buy" rating in a research note on Tuesday, October 1st. One equities research analyst has rated the stock with a hold rating, four have assigned a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, Haleon currently has a consensus rating of "Buy" and an average price target of $10.95.

Haleon Profile

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands.